TQB2930 not checked
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TQB2930 injection is a HER2 bispecific antibody drug; Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.”In the company’s words, NCT07047365 on ClinicalTrials.gov
- Tested for
- HER2-positive Advanced Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies, Colorectal Cancer, Advanced Solid Tumor
- Main trialPhase 3
- “TQB2930 is a HER2 bispecific antibody drug. This study aims to evaluate the efficacy and safety of TQB2930 combined with investigator's choice of chemotherapy versus trastuzumab combined with investigator's choice of chemotherapy in subjects with HER2-positive advanced breast cancer who have received at least two prior lines of anti-HER2 therapy in the advanced station.”In the company’s words, NCT07047365 on ClinicalTrials.gov
Other drugs for HER2-positive Advanced Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up4
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Mar 2028Phase 1/2 trial completes · ClinicalTrials.gov
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2028 | TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer | |
| Phase 1/2Recruiting | Dec 2026 | A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | |
| Phase 1/2Recruiting | Jun 2027 | A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer. | |
| Phase 1/2Recruiting | Mar 2028 | Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors | |
| Phase 1Unknown | Apr 2023 | Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026